Sirtris
CompanyUnited States
Sirtris develops one asset, in phase 1 (srt2104 in chronic obstructive pulmonary disease). Mostly small molecule acting on Mitochondrial biogenesis (PGC-1α), sirtuin signalling and SIRT1; based in the United States.
- Assets
- 1
- Furthest
- Phase 1
- Trials
- 7
- Signals
- 0
Pipeline
1Small-molecule activator of sirtuin 1 (SIRT1).
Phase 1Small moleculeMitochondrial biogenesis (PGC-1α)Sirtuin signallingchronic obstructive pulmonary diseasetype 2 diabetes
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms5
- Trials7
- Similar companies6
Updated 7 Oct 2026 · 13 sources